EGPAF, with funding and support from Unitaid and DNDi, is bringing new-to-market pediatric ARV formulations to full-scale implementation in eight African countries. We gathered and documented lessons learned from these eight project countries to inform, streamline and accelerate the introduction and roll-out of new, child-friendly ARVs so that all children living with HIV have access to optimal, WHO-recommended treatment and care.
Explore Related Resources
Issue Briefs
Accelerating Progress to Ending Pediatric HIV
Published March 2026
We are at a critical inflection point for children affected by HIV. In 2024 alone, 120,000 children were newly infected, and, without timely treatment, half of HIV positive infants will not reach their second birthday. Children remain left behind—a child with HIV is 6 times more likely to die than an adult without timely diagnosis. […]
View Resource
Topics:
HIV,
Pediatric HIV
Countries:
Global
Resource
Protecting Lives, Sustaining Progress
Published March 2026
The following landscape analysis of maternal and child health, HIV prevention, diagnosis, and treatment, and the historic strength of U.S. leadership in global aid provides an overview of these key areas of global health and recommendations for U.S. Congressional engagement and prioritization.
View Resource
Topics:
Advocacy,
Children,
Global Health Security,
Health System Strengthening,
HIV,
Maternal and Child Health,
Mothers and Infants,
Women
February 2022, HEALTH CENTER OF MACIA, Locality Macia, District of Xai Xai, Gaza Province, Mozambique. Delivering a ARVs Bottle in a private pharmacy.
Journal Articles
HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique
Published January 2025
Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. We assessed HIVDR rates and patterns in clients with virological failure (VF) after switching from an NNRTI-based regimen to TLD. A cross-sectional study was conducted in Gaza, Mozambique (August 2021–February 2022), including adults on first-line ART for ≥12 months […]
View Resource
Topics:
HIV
Countries:
Mozambique